Share Price and Basic Stock Data
Last Updated: November 13, 2025, 9:10 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Indoco Remedies Ltd operates in the pharmaceuticals sector and reported a market capitalization of ₹2,520 Cr. The company’s sales figures have shown a fluctuating trend over recent quarters. For instance, sales stood at ₹1,669 Cr for the year ending March 2023, which increased to ₹1,817 Cr for March 2024. However, the trailing twelve months (TTM) revenue was ₹1,671 Cr, indicating a slight decline compared to the previous fiscal year. Quarterly sales figures reveal a peak of ₹482 Cr in September 2023, followed by a decline to ₹459 Cr in December 2023. Such volatility in revenue can be attributed to various factors, including market competition and operational challenges, which may be common in the pharmaceutical industry. The company’s operational profit margin (OPM) has also shown a downward trend, recorded at 4% overall, reflecting challenges in cost management and pricing strategies.
Profitability and Efficiency Metrics
Indoco Remedies Ltd reported a net profit of ₹-116 Cr for the year ending March 2025, a significant decline from a net profit of ₹142 Cr in March 2023. The company’s operating profit margin (OPM) has deteriorated from 21% in March 2022 to just 6% in March 2025, indicating substantial pressure on profitability. The interest coverage ratio (ICR) stood at 1.58x, suggesting that the company has a modest ability to cover its interest expenses with its operating income. Furthermore, the return on equity (ROE) was recorded at 7.02%, which is relatively low compared to typical sector standards. The cash conversion cycle (CCC) is concerning at 232 days, indicating inefficiencies in inventory management and receivables collection. These metrics highlight both profitability challenges and operational inefficiencies that could hinder future growth prospects.
Balance Sheet Strength and Financial Ratios
Indoco Remedies Ltd’s balance sheet reflects a total borrowing of ₹994 Cr against reserves of ₹1,004 Cr, resulting in a total debt-to-equity ratio of 0.95, indicating a high level of leverage. This high leverage could pose risks, especially in an environment of rising interest rates. The company’s current ratio is reported at 1.24, suggesting that it maintains adequate liquidity to cover short-term obligations, which is a positive sign. However, the return on capital employed (ROCE) fell to -0.56%, indicating that the company is not generating adequate returns from its capital investments. Additionally, the price-to-book value (P/BV) ratio stood at 2.11x, which is relatively high and could indicate overvaluation in the current market context. Overall, while the company has some liquidity, its high leverage and poor returns raise concerns about long-term financial health.
Shareholding Pattern and Investor Confidence
Indoco Remedies Ltd’s shareholding pattern reveals that promoters hold 58.90% of the company’s shares, which demonstrates significant insider confidence. Foreign Institutional Investors (FIIs) own 1.22%, while Domestic Institutional Investors (DIIs) hold 18.96%. Public shareholding accounts for 20.82%, with a total of 33,129 shareholders as of March 2025. The stability of promoter holdings suggests a commitment to the company’s long-term vision despite recent financial struggles. However, the low FII presence may indicate a lack of broad investor confidence, particularly given the company’s recent financial performance. The decline in DII holdings from 19.56% in December 2023 to 18.75% in March 2025 may also raise flags about institutional sentiment. Such patterns could reflect concerns regarding profitability and operational efficiency in the face of increasing competition in the pharmaceutical sector.
Outlook, Risks, and Final Insight
The outlook for Indoco Remedies Ltd remains mixed. On one hand, the company’s solid promoter support and adequate liquidity position offer some reassurance. However, significant risks persist, including high leverage, declining profitability, and operational inefficiencies, which could impede growth. The pharmaceutical industry is highly competitive, and Indoco’s ability to adapt to market changes is crucial for future success. Potential strategies might include streamlining operations to enhance efficiency and focusing on cost management to improve profit margins. Furthermore, gaining investor confidence, particularly from FIIs, could bolster the company’s market position. In a best-case scenario, effective operational adjustments could lead to recovery in profitability, while in a worst-case scenario, ongoing challenges could exacerbate financial difficulties, requiring strategic restructuring to regain stability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Indoco Remedies Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 136 Cr. | 108 | 247/84.3 | 30.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,902 Cr. | 450 | 479/192 | 102 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 37.4 Cr. | 25.6 | 29.1/17.0 | 89.2 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,223.14 Cr | 1,187.86 | 55.63 | 201.16 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 408 | 433 | 399 | 428 | 426 | 482 | 459 | 450 | 431 | 433 | 411 | 390 | 438 |
| Expenses | 337 | 345 | 337 | 363 | 365 | 410 | 397 | 401 | 384 | 392 | 399 | 391 | 420 |
| Operating Profit | 71 | 88 | 62 | 65 | 61 | 71 | 63 | 49 | 48 | 40 | 12 | -1 | 18 |
| OPM % | 18% | 20% | 16% | 15% | 14% | 15% | 14% | 11% | 11% | 9% | 3% | -0% | 4% |
| Other Income | 1 | 0 | 0 | 0 | 0 | 4 | -6 | 22 | 1 | 2 | 2 | 2 | 2 |
| Interest | 4 | 5 | 7 | 9 | 8 | 8 | 10 | 12 | 14 | 18 | 16 | 18 | 26 |
| Depreciation | 20 | 16 | 17 | 18 | 20 | 21 | 24 | 26 | 28 | 29 | 29 | 29 | 30 |
| Profit before tax | 48 | 67 | 38 | 39 | 34 | 46 | 23 | 33 | 7 | -5 | -31 | -46 | -37 |
| Tax % | 20% | 26% | 26% | 34% | 29% | 24% | 31% | 33% | 74% | 107% | -8% | -9% | -1% |
| Net Profit | 39 | 50 | 28 | 26 | 24 | 35 | 16 | 22 | 2 | -10 | -28 | -41 | -36 |
| EPS in Rs | 4.19 | 5.40 | 3.05 | 2.80 | 2.65 | 3.81 | 1.77 | 2.46 | 0.28 | -1.04 | -2.86 | -4.38 | -3.88 |
Last Updated: August 1, 2025, 7:20 pm
Below is a detailed analysis of the quarterly data for Indoco Remedies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 438.00 Cr.. The value appears strong and on an upward trend. It has increased from 390.00 Cr. (Mar 2025) to 438.00 Cr., marking an increase of 48.00 Cr..
- For Expenses, as of Jun 2025, the value is 420.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 391.00 Cr. (Mar 2025) to 420.00 Cr., marking an increase of 29.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 19.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears strong and on an upward trend. It has increased from 0.00% (Mar 2025) to 4.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Interest, as of Jun 2025, the value is 26.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 8.00 Cr..
- For Depreciation, as of Jun 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -37.00 Cr.. The value appears strong and on an upward trend. It has increased from -46.00 Cr. (Mar 2025) to -37.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Jun 2025, the value is -1.00%. The value appears to be increasing, which may not be favorable. It has increased from -9.00% (Mar 2025) to -1.00%, marking an increase of 8.00%.
- For Net Profit, as of Jun 2025, the value is -36.00 Cr.. The value appears strong and on an upward trend. It has increased from -41.00 Cr. (Mar 2025) to -36.00 Cr., marking an increase of 5.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.88. The value appears strong and on an upward trend. It has increased from -4.38 (Mar 2025) to -3.88, marking an increase of 0.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 731 | 854 | 1,005 | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,671 |
| Expenses | 610 | 689 | 834 | 914 | 906 | 892 | 983 | 1,017 | 1,213 | 1,381 | 1,572 | 1,565 | 1,602 |
| Operating Profit | 120 | 166 | 171 | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 100 | 69 |
| OPM % | 16% | 19% | 17% | 15% | 13% | 8% | 11% | 18% | 21% | 17% | 13% | 6% | 4% |
| Other Income | 2 | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 1 | 20 | 6 | 7 |
| Interest | 19 | 11 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 | 38 | 66 | 78 |
| Depreciation | 31 | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 | 92 | 114 | 116 |
| Profit before tax | 72 | 110 | 99 | 91 | 48 | -9 | 29 | 132 | 237 | 193 | 136 | -74 | -118 |
| Tax % | 20% | 24% | 17% | 15% | 15% | -69% | 16% | 30% | 35% | 26% | 29% | 5% | |
| Net Profit | 58 | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -116 |
| EPS in Rs | 6.29 | 8.99 | 8.89 | 8.36 | 4.47 | -0.31 | 2.62 | 10.10 | 16.80 | 15.44 | 10.68 | -7.99 | -12.16 |
| Dividend Payout % | 22% | 18% | 18% | 19% | 22% | -95% | 11% | 15% | 13% | 15% | 14% | -2% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 43.10% | -1.20% | -6.10% | -46.75% | -107.32% | 900.00% | 287.50% | 66.67% | -8.39% | -31.69% | -180.41% |
| Change in YoY Net Profit Growth (%) | 0.00% | -44.31% | -4.89% | -40.66% | -60.56% | 1007.32% | -612.50% | -220.83% | -75.05% | -23.30% | -148.72% |
Indoco Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 3% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -263% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 5% |
| 3 Years: | -10% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| Last Year: | -7% |
Last Updated: September 5, 2025, 7:25 am
Balance Sheet
Last Updated: November 9, 2025, 2:15 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| Reserves | 439 | 500 | 558 | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,091 | 1,004 | 961 |
| Borrowings | 92 | 97 | 140 | 280 | 282 | 296 | 262 | 267 | 257 | 333 | 672 | 994 | 999 |
| Other Liabilities | 180 | 230 | 224 | 266 | 281 | 301 | 330 | 279 | 325 | 297 | 363 | 414 | 530 |
| Total Liabilities | 729 | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,508 |
| Fixed Assets | 325 | 340 | 374 | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 | 997 | 1,143 |
| CWIP | 44 | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 | 321 | 182 |
| Investments | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 1 | 1 |
| Other Assets | 360 | 443 | 496 | 666 | 613 | 605 | 631 | 677 | 809 | 864 | 1,057 | 1,111 | 1,182 |
| Total Assets | 729 | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,508 |
Below is a detailed analysis of the balance sheet data for Indoco Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
- For Reserves, as of Sep 2025, the value is 961.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,004.00 Cr. (Mar 2025) to 961.00 Cr., marking a decrease of 43.00 Cr..
- For Borrowings, as of Sep 2025, the value is 999.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 994.00 Cr. (Mar 2025) to 999.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 530.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 414.00 Cr. (Mar 2025) to 530.00 Cr., marking an increase of 116.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,508.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,430.00 Cr. (Mar 2025) to 2,508.00 Cr., marking an increase of 78.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,143.00 Cr.. The value appears strong and on an upward trend. It has increased from 997.00 Cr. (Mar 2025) to 1,143.00 Cr., marking an increase of 146.00 Cr..
- For CWIP, as of Sep 2025, the value is 182.00 Cr.. The value appears to be declining and may need further review. It has decreased from 321.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 139.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,182.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,111.00 Cr. (Mar 2025) to 1,182.00 Cr., marking an increase of 71.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,508.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,430.00 Cr. (Mar 2025) to 2,508.00 Cr., marking an increase of 78.00 Cr..
However, the Borrowings (999.00 Cr.) are higher than the Reserves (961.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 28.00 | 69.00 | 31.00 | -123.00 | -147.00 | -219.00 | -139.00 | -42.00 | 71.00 | -45.00 | -427.00 | -894.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 69 | 66 | 69 | 74 | 73 | 74 | 69 | 69 | 70 | 77 | 82 | 77 |
| Inventory Days | 148 | 181 | 174 | 189 | 203 | 209 | 230 | 245 | 248 | 228 | 230 | 307 |
| Days Payable | 95 | 146 | 137 | 166 | 157 | 195 | 183 | 117 | 107 | 86 | 100 | 152 |
| Cash Conversion Cycle | 122 | 102 | 105 | 97 | 119 | 88 | 116 | 197 | 212 | 219 | 212 | 232 |
| Working Capital Days | 44 | 46 | 48 | 41 | 38 | 21 | 22 | 59 | 78 | 82 | 62 | 39 |
| ROCE % | 17% | 21% | 17% | 12% | 7% | 1% | 6% | 16% | 23% | 17% | 10% | -0% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 4,199,230 | 0.57 | 150.56 | 4,199,230 | 2025-04-22 17:25:31 | 0% |
| Nippon India Small Cap Fund | 2,744,559 | 0.16 | 98.41 | 2,744,559 | 2025-04-22 17:25:31 | 0% |
| DSP Healthcare Fund | 2,275,954 | 2.64 | 81.6 | 2,275,954 | 2025-04-22 17:25:31 | 0% |
| Nippon India Pharma Fund | 1,834,924 | 0.75 | 65.79 | 1,834,924 | 2025-04-22 17:25:31 | 0% |
| Franklin India Smaller Companies Fund | 1,362,700 | 0.34 | 48.86 | 1,362,700 | 2025-04-22 02:06:43 | 0% |
| ICICI Prudential Smallcap Fund | 904,190 | 0.37 | 32.68 | 904,190 | 2025-04-22 17:25:31 | 0% |
| HDFC Capital Builder Value Fund - Regular Plan | 732,298 | 0.34 | 26.47 | 732,298 | 2025-04-22 17:25:31 | 0% |
| Tata India Pharma & HealthCare Fund | 276,851 | 0.85 | 10.01 | 276,851 | 2025-04-22 17:25:31 | 0% |
| DSP Multicap Fund | 60,558 | 0.13 | 2.17 | 60,558 | 2025-04-22 17:25:31 | 0% |
| Motilal Oswal BSE Healthcare ETF | 594 | 0.1 | 0.02 | 594 | 2025-04-22 17:25:31 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | -8.46 | 10.53 | 15.44 | 16.80 | 10.10 |
| Diluted EPS (Rs.) | -8.45 | 10.51 | 15.42 | 16.80 | 10.10 |
| Cash EPS (Rs.) | 3.89 | 20.49 | 23.10 | 25.37 | 18.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 110.79 | 120.47 | 111.58 | 98.17 | 83.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 110.79 | 120.47 | 111.58 | 98.17 | 83.45 |
| Revenue From Operations / Share (Rs.) | 180.48 | 197.14 | 181.07 | 167.20 | 134.73 |
| PBDIT / Share (Rs.) | 11.35 | 27.57 | 31.30 | 35.77 | 24.68 |
| PBIT / Share (Rs.) | -0.99 | 17.61 | 23.64 | 27.21 | 16.74 |
| PBT / Share (Rs.) | -8.06 | 14.73 | 20.92 | 25.67 | 14.32 |
| Net Profit / Share (Rs.) | -8.45 | 10.52 | 15.44 | 16.80 | 10.10 |
| NP After MI And SOA / Share (Rs.) | -7.99 | 10.68 | 15.44 | 16.80 | 10.10 |
| PBDIT Margin (%) | 6.28 | 13.98 | 17.28 | 21.39 | 18.31 |
| PBIT Margin (%) | -0.54 | 8.93 | 13.05 | 16.27 | 12.42 |
| PBT Margin (%) | -4.46 | 7.47 | 11.55 | 15.35 | 10.63 |
| Net Profit Margin (%) | -4.68 | 5.33 | 8.52 | 10.04 | 7.49 |
| NP After MI And SOA Margin (%) | -4.42 | 5.41 | 8.52 | 10.04 | 7.49 |
| Return on Networth / Equity (%) | -7.21 | 8.87 | 13.83 | 17.11 | 12.09 |
| Return on Capital Employeed (%) | -0.56 | 10.59 | 17.65 | 23.62 | 16.98 |
| Return On Assets (%) | -3.03 | 4.59 | 8.57 | 10.41 | 7.07 |
| Long Term Debt / Equity (X) | 0.52 | 0.31 | 0.13 | 0.10 | 0.12 |
| Total Debt / Equity (X) | 0.95 | 0.59 | 0.30 | 0.26 | 0.27 |
| Asset Turnover Ratio (%) | 0.72 | 0.95 | 1.06 | 1.10 | 0.95 |
| Current Ratio (X) | 1.24 | 1.56 | 1.90 | 1.82 | 1.53 |
| Quick Ratio (X) | 0.72 | 0.98 | 1.14 | 1.09 | 0.94 |
| Inventory Turnover Ratio (X) | 4.31 | 1.43 | 1.29 | 1.44 | 1.36 |
| Dividend Payout Ratio (NP) (%) | -18.75 | 21.05 | 14.57 | 8.92 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 34.47 | 10.89 | 9.74 | 5.91 | 0.00 |
| Earning Retention Ratio (%) | 118.75 | 78.95 | 85.43 | 91.08 | 0.00 |
| Cash Earning Retention Ratio (%) | 65.53 | 89.11 | 90.26 | 94.09 | 0.00 |
| Interest Coverage Ratio (X) | 1.58 | 6.68 | 11.52 | 23.31 | 10.21 |
| Interest Coverage Ratio (Post Tax) (X) | -0.19 | 3.25 | 6.68 | 11.95 | 5.18 |
| Enterprise Value (Cr.) | 3109.49 | 3659.62 | 3301.12 | 3694.36 | 2857.47 |
| EV / Net Operating Revenue (X) | 1.87 | 2.01 | 1.98 | 2.40 | 2.30 |
| EV / EBITDA (X) | 29.70 | 14.40 | 11.45 | 11.21 | 12.57 |
| MarketCap / Net Operating Revenue (X) | 1.29 | 1.67 | 1.80 | 2.25 | 2.14 |
| Retention Ratios (%) | 118.75 | 78.94 | 85.42 | 91.07 | 0.00 |
| Price / BV (X) | 2.11 | 2.73 | 2.92 | 3.84 | 3.46 |
| Price / Net Operating Revenue (X) | 1.29 | 1.67 | 1.80 | 2.25 | 2.14 |
| EarningsYield | -0.03 | 0.03 | 0.04 | 0.04 | 0.03 |
After reviewing the key financial ratios for Indoco Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.46. This value is below the healthy minimum of 5. It has decreased from 10.53 (Mar 24) to -8.46, marking a decrease of 18.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is -8.45. This value is below the healthy minimum of 5. It has decreased from 10.51 (Mar 24) to -8.45, marking a decrease of 18.96.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.89. This value is within the healthy range. It has decreased from 20.49 (Mar 24) to 3.89, marking a decrease of 16.60.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 110.79. It has decreased from 120.47 (Mar 24) to 110.79, marking a decrease of 9.68.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 110.79. It has decreased from 120.47 (Mar 24) to 110.79, marking a decrease of 9.68.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 180.48. It has decreased from 197.14 (Mar 24) to 180.48, marking a decrease of 16.66.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.35. This value is within the healthy range. It has decreased from 27.57 (Mar 24) to 11.35, marking a decrease of 16.22.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.99. This value is below the healthy minimum of 0. It has decreased from 17.61 (Mar 24) to -0.99, marking a decrease of 18.60.
- For PBT / Share (Rs.), as of Mar 25, the value is -8.06. This value is below the healthy minimum of 0. It has decreased from 14.73 (Mar 24) to -8.06, marking a decrease of 22.79.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -8.45. This value is below the healthy minimum of 2. It has decreased from 10.52 (Mar 24) to -8.45, marking a decrease of 18.97.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.99. This value is below the healthy minimum of 2. It has decreased from 10.68 (Mar 24) to -7.99, marking a decrease of 18.67.
- For PBDIT Margin (%), as of Mar 25, the value is 6.28. This value is below the healthy minimum of 10. It has decreased from 13.98 (Mar 24) to 6.28, marking a decrease of 7.70.
- For PBIT Margin (%), as of Mar 25, the value is -0.54. This value is below the healthy minimum of 10. It has decreased from 8.93 (Mar 24) to -0.54, marking a decrease of 9.47.
- For PBT Margin (%), as of Mar 25, the value is -4.46. This value is below the healthy minimum of 10. It has decreased from 7.47 (Mar 24) to -4.46, marking a decrease of 11.93.
- For Net Profit Margin (%), as of Mar 25, the value is -4.68. This value is below the healthy minimum of 5. It has decreased from 5.33 (Mar 24) to -4.68, marking a decrease of 10.01.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -4.42. This value is below the healthy minimum of 8. It has decreased from 5.41 (Mar 24) to -4.42, marking a decrease of 9.83.
- For Return on Networth / Equity (%), as of Mar 25, the value is -7.21. This value is below the healthy minimum of 15. It has decreased from 8.87 (Mar 24) to -7.21, marking a decrease of 16.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 10. It has decreased from 10.59 (Mar 24) to -0.56, marking a decrease of 11.15.
- For Return On Assets (%), as of Mar 25, the value is -3.03. This value is below the healthy minimum of 5. It has decreased from 4.59 (Mar 24) to -3.03, marking a decrease of 7.62.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.52. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.52, marking an increase of 0.21.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has increased from 0.59 (Mar 24) to 0.95, marking an increase of 0.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has decreased from 0.95 (Mar 24) to 0.72, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 1.5. It has decreased from 1.56 (Mar 24) to 1.24, marking a decrease of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 0.72. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.72, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.31. This value is within the healthy range. It has increased from 1.43 (Mar 24) to 4.31, marking an increase of 2.88.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -18.75. This value is below the healthy minimum of 20. It has decreased from 21.05 (Mar 24) to -18.75, marking a decrease of 39.80.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 34.47. This value is within the healthy range. It has increased from 10.89 (Mar 24) to 34.47, marking an increase of 23.58.
- For Earning Retention Ratio (%), as of Mar 25, the value is 118.75. This value exceeds the healthy maximum of 70. It has increased from 78.95 (Mar 24) to 118.75, marking an increase of 39.80.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 65.53. This value is within the healthy range. It has decreased from 89.11 (Mar 24) to 65.53, marking a decrease of 23.58.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 3. It has decreased from 6.68 (Mar 24) to 1.58, marking a decrease of 5.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 3. It has decreased from 3.25 (Mar 24) to -0.19, marking a decrease of 3.44.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,109.49. It has decreased from 3,659.62 (Mar 24) to 3,109.49, marking a decrease of 550.13.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.87, marking a decrease of 0.14.
- For EV / EBITDA (X), as of Mar 25, the value is 29.70. This value exceeds the healthy maximum of 15. It has increased from 14.40 (Mar 24) to 29.70, marking an increase of 15.30.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.29. This value is within the healthy range. It has decreased from 1.67 (Mar 24) to 1.29, marking a decrease of 0.38.
- For Retention Ratios (%), as of Mar 25, the value is 118.75. This value exceeds the healthy maximum of 70. It has increased from 78.94 (Mar 24) to 118.75, marking an increase of 39.81.
- For Price / BV (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 2.11, marking a decrease of 0.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.29. This value is within the healthy range. It has decreased from 1.67 (Mar 24) to 1.29, marking a decrease of 0.38.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to -0.03, marking a decrease of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indoco Remedies Ltd:
- Net Profit Margin: -4.68%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.56% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -7.21% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.19
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 55.63)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.95
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -4.68%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Indoco House, 166, CST Road, Kalina, Mumbai Maharashtra 400098 | compliance.officer@indoco.com http://www.indoco.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suresh G Kare | Chairman |
| Ms. Aditi Panandikar | Managing Director |
| Mr. Sundeep V Bambolkar | Joint Managing Director |
| Dr. Anand Nadkarni | Non Executive Director |
| Mr. Satish Shenoy | Independent Director |
| Mr. Ajay Mulgaokar | Independent Director |
| Dr.(Ms.) Vasudha V Kamat | Independent Director |
| Mr. Abhijit Y Gore | Independent Director |
FAQ
What is the intrinsic value of Indoco Remedies Ltd?
Indoco Remedies Ltd's intrinsic value (as of 13 November 2025) is 89.36 which is 66.53% lower the current market price of 267.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,465 Cr. market cap, FY2025-2026 high/low of 355/190, reserves of ₹961 Cr, and liabilities of 2,508 Cr.
What is the Market Cap of Indoco Remedies Ltd?
The Market Cap of Indoco Remedies Ltd is 2,465 Cr..
What is the current Stock Price of Indoco Remedies Ltd as on 13 November 2025?
The current stock price of Indoco Remedies Ltd as on 13 November 2025 is 267.
What is the High / Low of Indoco Remedies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Indoco Remedies Ltd stocks is 355/190.
What is the Stock P/E of Indoco Remedies Ltd?
The Stock P/E of Indoco Remedies Ltd is .
What is the Book Value of Indoco Remedies Ltd?
The Book Value of Indoco Remedies Ltd is 106.
What is the Dividend Yield of Indoco Remedies Ltd?
The Dividend Yield of Indoco Remedies Ltd is 0.07 %.
What is the ROCE of Indoco Remedies Ltd?
The ROCE of Indoco Remedies Ltd is 0.49 %.
What is the ROE of Indoco Remedies Ltd?
The ROE of Indoco Remedies Ltd is 7.02 %.
What is the Face Value of Indoco Remedies Ltd?
The Face Value of Indoco Remedies Ltd is 2.00.